Hepatitis C News and Research

Latest Hepatitis C News and Research

CSL Behring donates life-saving medicines to assist earthquake victims in Haiti

Direct Relief International announced today that CSL Behring has donated life-saving medicines valued at more than $100,000 to assist earthquake victims in Haiti who are at risk of tetanus or hepatitis B infections. The products will be used in clinics at Hopital Albert Schweitzer in Deschapelles.

14 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex, Inc. today announced its financial results for the first quarter ended March 31, 2010. The Company also announced that it has initiated a Phase I single ascending dose trial of INX-189, its lead HCV nucleotide polymerase inhibitor, in healthy volunteers under an Investigational New Drug application with the U.S. Food and Drug Administration.

14 May 2010

Report examines vaccine costs, access in low-income countries

A recent report by Medecins Sans Frontieres (MSF) and Oxfam International warns "that the global campaign to vaccinate children in poor countries is being hampered by high prices and is facing an acute funding crisis," BMJ News reports.

14 May 2010

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

14 May 2010

Pharmasset prices underwritten public offering of common stock

Pharmasset, Inc. announced today the pricing of an underwritten public offering of 3,200,000 shares of its common stock at an offering price of $29.00 per share. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $87.9 million.

14 May 2010

MitoSciences awarded $590,000 to support development of companion diagnostic tests for antiviral drugs

MitoSciences announces that it has just been awarded $590,000 by the National Institutes of Health to support the development of companion diagnostic tests for antiviral drugs. The award was made after competitive scientific review and was issued under The American Recovery and Reinvestment Act of 2009.

14 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Palatin Technologies, Inc., a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010.

13 May 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

A new review on the Amazon website suggests that the natural antiviral supplement Gene-Eden may be effective in reducing the Hepatitis C viral load in people infected with the virus.

13 May 2010

Medco announces new $3 billion share repurchase program

Medco Health Solutions, Inc. today announced that its Board of Directors has unanimously approved a new $3 billion share repurchase program.

13 May 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Achillion Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 May 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

Sex can affect frequency and severity of adverse effects of vaccination

Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.

13 May 2010

Seaside purchases NanoViricides' Series B Convertible Preferred Stock for gross proceeds of $5M

NanoViricides, Inc., announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf "Form S-3" offering. The registered shelf offering became effective on April 29, 2010.

12 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.

12 May 2010